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Association of b-Defensin Copy Number and
Psoriasis in Three Cohorts of European Origin
Philip E. Stuart1,5, Ulrike Hu¨ffmeier2,5, Rajan P. Nair1,5, Raquel Palla3,5, Trilokraj Tejasvi1, Joost Schalkwijk4,
James T. Elder1,6, Andre Reis2,6 and John A.L. Armour3,6
A single previous study has demonstrated significant association of psoriasis with copy number of b-defensin
genes, using DNA from psoriasis cases and controls from Nijmegen and Erlangen. In this study, we attempted to
replicate that finding in larger new cohorts from Erlangen (N¼ 2,017) and Michigan (N¼ 5,412), using improved
methods for b-defensin copy number determination based on the paralog ratio test, and enhanced methods of
analysis and association testing implemented in the CNVtools resource. We demonstrate that the association
with psoriasis found in the discovery sample is maintained after applying improved typing and analysis methods
(P¼ 5.5 104, odds ratio (OR)¼ 1.25). We also find that the association is replicated in 2,616 cases and 2,526
controls from Michigan, although at reduced significance (P¼ 0.014), but not in new samples from Erlangen
(1,396 cases and 621 controls, P¼ 0.38). Meta-analysis across all cohorts suggests a nominally significant
association (P¼ 6.6 103/2 104) with an effect size (OR¼ 1.081) much lower than found in the discovery
study (OR¼ 1.32). This reduced effect size and significance on replication is consistent with a genuine but weak
association.
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INTRODUCTION
Psoriasis is a common and chronic inflammatory disease of
the skin found at high frequency in European populations.
Cellular features of psoriasis include changes to keratinocyte
differentiation and epidermal hyperplasia, and there is strong
evidence for the role of immune, inflammatory, and genetic
factors predisposing individuals to disease. A very strong
association of psoriasis with HLA-Cw6 (PSORS1) has long
been established, providing unambiguous evidence of the
importance of genetic variation in psoriasis. Although
PSORS1 harbors the strongest genetic risk factor, it is clear
that many other loci contribute to genetic susceptibility.
Several laboratories recently performed well-powered gen-
ome-wide association studies of psoriasis and, in addition to
confirming previously known loci, were able to establish
genome-wide significant association for 20 new psoriasis
susceptibility loci, many of which contained genes with
functions in the immune system and inflammation (Cargill
et al., 2007; Capon et al., 2008; de Cid et al., 2009;
Nair et al., 2009; Zhang et al., 2009; Ellinghaus et al.,
2010; Genetic Analysis of Psoriasis Consortium et al., 2010;
Hu¨ffmeier et al., 2010; Stuart et al., 2010; Sun et al., 2010).
Among the loci identified in genome-wide association
studies, one risk factor is defined by a copy number variant
(CNV), a deletion of the LCE3B and LCE3C genes important
in establishing the skin’s barrier functions (de Cid et al.,
2009).
A cluster of seven human b-defensin genes on chromo-
some 8, including DEFB4, DEFB103-107, and SPAG11, but
excluding DEFB1, display extensive variation in copy
number. Copy numbers commonly range between 2 and 7
copies in European populations, with occasional examples of
copy numbers as high as 10 or 12, and the repeat unit
appears coherent, with all copy-variable genes having equal
copy number in each individual (Hollox et al., 2003;
Linzmeier and Ganz, 2005; Groth et al., 2008). Copy
numbers in the range of 2–7 per diploid genome create real
challenges for accurate typing, and for multi-allelic CNVs in
particular; the precision and reliability of copy number
measurement is a key factor in ensuring that association
findings are robust (McCarroll, 2008; Aldhous et al., 2010).
The hBD-2 peptide can be found at very high levels in
psoriatic plaques, and it is natural to hypothesize that CNV of
the gene DEFB4, encoding hBD-2, might be a genetic factor
in predisposition to psoriasis. Hollox et al. (2008) published a
study of samples from 179 Dutch cases and 272 controls, and
& 2012 The Society for Investigative Dermatology www.jidonline.org 2407
ORIGINAL ARTICLE
Received 25 November 2011; revised 12 April 2012; accepted 22 April 2012;
published online 28 June 2012
1Department of Dermatology, University of Michigan, 1500 East Medical
Center Drive, Ann Arbor, Michigan, USA; 2Institute of Human Genetics,
University Hospital Erlangen, Friedrich-Alexander-University
Erlangen-Nuremberg, Erlangen, Germany; 3School of Biology, University of
Nottingham, Queen’s Medical Centre, Nottingham, UK and 4Department of
Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands
Correspondence: John A.L. Armour, School of Biology, University of
Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH, UK.
E-mail: John.Armour@nottingham.ac.uk
5Joint first authors
6Joint senior authors
Abbreviations: CNV, copy number variant; OR, odds ratio; PRT, paralog ratio
test
319 German psoriasis patients and 305 controls. In both
cohorts they found significantly elevated mean copy number
in cases relative to controls (Po104 in both cohorts),
consistent with a linear-effect model in which each addi-
tional repeat unit multiplies the risk of psoriasis by an odds
ratio of about 1.3. Using improved statistical approaches,
Barnes et al. (2008) reanalyzed the data from Hollox et al.,
concluding that while there was some evidence for differ-
ential bias in the typing of the German samples, the
underlying association appeared to be valid.
This finding, which is of great interest in the pathogenesis
of psoriasis, is based on relatively small sample sizes, and no
published study has yet attempted to replicate this finding
independently. Here we attempt to replicate the association
results using DNA samples from more than 4,000 psoriasis
cases (predominantly chronic plaque or guttate psoriasis, and
including psoriatic arthritis, see Supplementary Material
online, section F) and 3,000 controls from two centers; we
also retyped and analyzed most of the samples from the
original study using improved CNV measurement methods.
RESULTS
Copy number determination: quality parameters
Where genotyping is error-prone, there are opposite dangers
in either accepting all data without selection (uncensored) or
in applying a quality threshold, and accepting only data
passing the threshold (censored). In a particular case of the b-
defensin genes, one would expect measurement error to be
most problematic at high copy number, and therefore that the
application of a strict quality threshold would preferentially
remove samples at the high end of the range. If applied
differentially to cases and controls, censoring could create an
artifactual association with copy number. For this reason, we
show results from uncensored data in this report, but for
completeness we have also analysed the corresponding
censored data, summarized in the Supplementary Material
online. The overall conclusions from our work are not
strongly affected by the choice of censored or uncensored
data (Supplementary Figures S1 and S2; Tables S1 and S2
online).
Association testing
Bar graphs of the most likely copy numbers from the fitting
procedure for uncensored data are shown in Figure 1 (with
corresponding distributions for censored data in Supplemen-
tary Figure S3 online). These bar graphs are for illustrative
purposes only; these integer assignments are not used for the
actual association tests, which incorporate posterior probabil-
ities across all possible copy numbers along with uncertainties
in the probabilities themselves. These bar graphs give the
impression that there are relatively strong positive associations
between psoriasis and defensin copy number in the original
Erlangen and all Nijmegen samples, modest positive associa-
tions in the Michigan sample and the full Erlangen sample,
and no association in the new Erlangen sample.
Basic properties of data sets from the different cohorts
examined are given in Supplementary Table S3 online, with
results from association testing using uncensored data
summarized in Table 1; a corresponding summary of
association testing outcomes for censored data is given in
Supplementary Table S4 online. The uncensored Nijmegen
discovery sample (Table 1) shows moderately strong associa-
tion for the HSPD21, paralog ratio test (PRT) mean, and triplex
assays (odds ratio (OR)¼ 1.313–1.386; P¼ 0.0087–0.0030),
but is nonsignificant for the PRT107A assay (OR¼1.200,
P¼0.11). This is a somewhat less significant association than
reported in the original Hollox study (Hollox et al., 2008) for
the Nijmegen cohort (P¼0.01–1.65106 depending upon
CNV assay), but a precise comparison is impossible as the
CNV assays, sample inclusion, and methods of analysis all
differ. However, reanalysis of the original Hollox study data
(Barnes et al., 2008), using an early version of CNVtools,
found significance of association (P¼ 0.002) of the same order
of magnitude as this analysis of the retyped samples.
Censoring the Nijmegen discovery sample lessens the
significance but not the strength of the association, indicating
a reduction in power caused by the reduction in sample size
(Supplementary Table S4 online).
Association for the retyped and uncensored Erlangen
cohort (Table 1; OR¼1.214, P¼0.02) is much weaker than
first reported (P¼2.9 105–9.0 106), which reflects
strong case–control bias, uncorrected in the original analysis,
which artifactually inflated the association signal. In the
current analysis of the Erlangen discovery sample, a case–-
control batch term was included when modeling both peak
means and variances. The Barnes et al. (2008) reanalysis of
the original Erlangen data set also found strong differential
bias between cases and controls; after bias correction their
analysis yielded a reduced association P-value of 0.02,
identical to this analysis for the retyped data. Censoring has
little effect on the strength (odds ratio) or significance
(P-value) of the association (Supplementary Table S4 online).
The independent samples from Erlangen and Michigan
(Table 1) are much larger than the original or retyped discovery
samples, providing a powerful replication set for assessing the
robustness of the original finding. The uncensored Erlangen
replication sample shows a weak nonsignificant trend toward
association (OR¼1.039, P¼ 0.38), and the uncensored
Michigan sample shows a small but nominally significant
association (OR¼ 1.066, P¼0.014). When an association
study of a candidate locus is such that it has borderline or low
power for finding genome-wide significance, yet it does
indeed find genome-wide significance, this is usually due to
the effect size (odds ratio) for the locus in that particular
sample being, by chance, considerably larger than its true
value in the underlying population. When this positive finding
is followed up with a sample equal or larger in size to the
original, the estimate of the odds ratio in the replication
sample tends to be lower than in the first and closer to its true
value, a phenomenon known as the ‘‘winner’s curse’’
(Lohmueller et al., 2003). The weaker association in the
replication samples compared with the retyped discovery
samples is a good illustration of the winner’s curse in action,
and we assume that these estimated odds ratios are probably a
better estimate of the true strength of association in people of
European descent than those estimated from the discovery
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samples. As expected, adding 28 new individuals to the
retyped Nijmegen sample had little impact on the association
test results. The combined (newþ old) Erlangen sample shows
a modest association (OR¼1.085, P¼0.033) intermediate
between the results obtained for the discovery and replication
subsets (Table 1).
Table 2 presents the results of meta-analysis for association
across cohorts for uncensored data, with the corresponding
results for censored data shown in Supplementary Table S5
online. Meta-analysis of the retyped discovery samples for the
Nijmegen and Erlangen cohorts shows substantial association
for uncensored data when using the HSPD21, mean PRT, or
triplex assays for the Nijmegen sample (OR¼1.252–1.273,
P¼5.5104–2.5104, Table 2). The combined discovery
results are slightly weaker when using the PRT107A assay for
the Nijmegen sample (OR¼ 1.210, P¼ 0.0047). The associa-
tion for the non-PRT107A data for the combined retyped
discovery samples is substantially less significant than
reported in the supplement to the original Hollox et al. study
(P¼3108), but within an order of magnitude of what was
found by the Barnes et al. CNVtools reanalysis of the original
discovery typings (P¼6.5 105). This indicates that the
reduction in significance in this analysis compared with the
original report is probably mostly a consequence of bias
correction in the Erlangen cohort, and not of other differences
such as retyping, DNA re-extraction, new CNV assays, or
slightly different sample composition.
Random and fixed effects meta-analyses of the two
discovery samples give identical results, and there is no
significant heterogeneity in the effect size (ORs) for the retyped
Nijmegen and Erlangen cohorts (Cochran’s Q¼0.004–0.91,
P¼0.95–0.34; I2¼0.0). Censoring the discovery samples
resulted in somewhat weaker association (OR¼ 1.211–1.245,
P¼0.0025–0.0073), presumably a consequence of the re-
duced sample size for the Dutch cohort (Supplementary Table
S5 online). Meta-analysis of uncensored data across all
discovery and replication cohorts (Table 2) gives an OR of
1.076–1.083 (P¼4.7104–1.5 104) under a fixed effects
model. Meta-analysis of the two replication cohorts (Michigan
and Erlangen) yields an association much weaker in strength
and significance than the discovery cohort, for both the
uncensored (Table 2; OR¼1.059, P¼0.010) and censored
(Supplementary Table S5 online; OR¼ 1.059, P¼0.012) data.
There is no apparent heterogeneity. Hence, the replication
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Figure 1. Distributions of copy number values for b-defensins. Bar graphs illustrating distributions of most likely copy numbers determined in CNVtools by
fitting Gaussian mixture distributions to copy number variant measurements in the uncensored (a) Michigan samples, (b) Erlangen samples, and
(c) Nijmegen samples. PRT, paralog ratio test.
www.jidonline.org 2409
PE Stuart et al.
b-Defensins in Psoriasis
data are only weakly confirmatory of the original finding.
Because of the winner’s curse, the odds ratio of 1.059 for the
association of the combined replication samples is a less
biased estimate of the effect size in the underlying population
than either the OR of the discovery or combined replication
and discovery samples.
In this analysis, the increase in fit afforded by the allelic
association model was never significantly better than the fit
afforded by the linear model, so the results of the linear
association model were chosen for simplicity and power.
Under a linear model, any possible odds ratio between two
copy number states can be computed from the single OR that
Table 1. Single cohort association tests (uncensored)
Linear trend model
Cohort Subset Assay
No. of cases/
controls OR 95% CI P-value
Allelic model
P-value
P-value for test of fit
of allelic versus linear
trend model
Michigan All HSPD21 2,616/2,526 1.066 1.013–1.121 0.014 0.46 0.98
Erlangen All HSPD5 1,696/910 1.085 1.007–1.169 0.033 0.45 0.90
New HSPD5 1,396/621 1.039 0.953–1.133 0.38 0.86 0.87
Old HSPD5 300/289 1.214 1.031–1.428 0.020 0.21 0.79
Nijmegen All HSPD21 187/238 1.343 1.093–1.649 0.0049 0.057 0.59
PRT107A 152/229 1.200 0.968–1.488 0.096 0.41 0.69
PRT mean 188/246 1.343 1.105–1.632 0.0031 0.036 0.53
Triplex 188/246 1.288 1.063–1.560 0.0098 0.18 0.92
Old HSPD21 170/230 1.386 1.114–1.724 0.0034 0.087 0.91
PRT107A 137/219 1.202 0.958–1.509 0.11 0.35 0.55
PRT mean 171/235 1.370 1.113–1.687 0.0030 0.053 0.71
Triplex 171/235 1.313 1.071–1.610 0.0087 0.14 0.83
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 2. Meta-analyses (uncensored)
Association (fixed effects)
Association
(random effects) Heterogeneity
Stage Cohorts
No. of cases/
controls
Meta-OR
(95% CI) Meta-P
Meta-OR
(95% CI) Meta-P
Cochran’s Q
(P-value)
I2
(95% CI)
Discovery Erlangen (old)+Nijmegen
(old, HSPD21)
472/519 1.273 (1.117–1.450) 3.0E-04 1.273 (1.117–1.450) 3.0E-04 0.91 (0.34) 0.0 (—)
Erlangen (old)+Nijmegen
(old, PRT107A)
440/508 1.210 (1.060–1.381) 4.7E-03 1.210 (1.060–1.381) 4.7E-03 0.004 (0.95) 0.0 (—)
Erlangen (old)+Nijmegen
(old, mean PRT)
473/524 1.271 (1.118–1.445) 2.5E-04 1.271 (1.118–1.445) 2.5E-04 0.81 (0.37) 0.0 (—)
Erlangen (old)+Nijmegen
(old, triplex)
473/524 1.252 (1.102–1.422) 5.5E-04 1.252 v1.102–1.422) 5.5E-04 0.35 (0.55) 0.0 (—)
Replication Michigan+Erlangen (new) 4,014/3,147 1.059 (1.014–1.106) 1.0E-02 1.059 (1.014–1.106) 1.0E-02 0.24 (0.62) 0.0 (—)
Combined Michigan+Erlangen
(all)+Nijmegen (all, HSPD21)
4,502/3,674 1.081 (1.038–1.127) 1.9E-04 1.102 (1.021–1.189) 1.3E-02 4.58 (0.10) 56.3 (0.0–87.6)
Michigan+Erlangen
(all)+Nijmegen (all,
PRT107A)
4,468/3,665 1.076 (1.033–1.121) 4.7E-04 1.076 (1.033–1.121) 4.7E-04 1.18 (0.56) 0.0 (0.0–82.3)
Michigan+Erlangen
(all)+Nijmegen (all, mean
PRT)
4,503/3,682 1.083 (1.039–1.128) 1.5E-04 1.107 (1.021–1.200) 1.4E-02 5.15 (0.077) 61.1 (0.0–88.9)
Michigan+Erlangen
(all)+Nijmegen (all, triplex)
4,503/3,682 1.081 (1.037–1.126) 2.0E-04 1.093 (1.025–1.165) 6.6E-03 3.51 (0.17) 43.0 (0.0–72.6)
Abbreviations: CI, confidence interval; OR, odds ratio; PRT, paralog ratio test.
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is reported. Therefore, the ORs for copy number classes
differing by 2, 3, 4, or 5 copies would be estimated from our
data as 1.121, 1.188, 1.258, and 1.332, respectively (i.e.,
1.059 raised to the second, third, fourth, and fifth powers).
Censoring has only a small effect on the meta-analysis of the
combined discovery and replication sets (Table 2, Supple-
mentary Table S5 online).
DISCUSSION
The new data presented in this report confirm the significant
positive association found in the original cohorts from
Nijmegen and Erlangen, and replicate this association at a
nominally significant level in a newly typed cohort from
Michigan (P¼0. 014, Table 1) but not in new samples from
Erlangen (P¼ 0.38). Meta-analysis (Table 2) combining more
than 8,000 discovery and replication samples suggests a
significant but weak effect (P¼ 2104, OR¼1.081), a
much smaller effect size than the OR of 1.32 implied by the
Hollox et al. data. This is certainly a weak level of
association, less than the reported OR for any of the other
24 currently known psoriasis susceptibility loci with con-
vincing associations (Cargill et al., 2007; Capon et al., 2008;
de Cid et al., 2009; Nair et al., 2009; Zhang et al., 2009;
Ellinghaus et al., 2010; Genetic Analysis of Psoriasis
Consortium et al., 2010; Hu¨ffmeier et al., 2010; Stuart
et al., 2010; Sun et al., 2010), all of which have reported ORs
of 1.10 or greater. However, these other associated loci are
biallelic variations, and the highly variable b-defensin CNV
commonly ranges from 2 to 7 total copies. Under a linear
trend model, applying the OR of 1.059 given by the
replication sample meta-analysis suggests that people with
seven copies of the b-defensin CNV have 1.332 times the
odds of having psoriasis compared with people with two
copies of the CNV, a substantial increase in risk. Associa-
tions of this CNV with psoriasis may suggest the b-defensins
as new targets for therapeutic intervention in controlling
inflammation.
The combined sample size across all three collaborating
groups is 8,185 individuals (4,503 cases and 3,682 controls)
for the uncensored data. This represents the most powerful
sample to date for testing association of the b-defensin CNV
and psoriasis, yet the P-value under a random effects meta-
analysis is of only modest significance (P¼0.0066). Current
standards for complex genetic diseases require candidate
disease loci to reach genome-wide levels of significance of
association before they are considered to be established as
susceptibility loci. This is true even for studies of a single
functional candidate such as this one. As the a priori
probability that any given locus in the human genome is
truly associated with a complex disease is very low, the
chance of a type I error is much higher than the nominal
level of the test. For studies of SNP markers in people of
European descent, the genome-wide level of significance
has been determined to be a nominal P-value of B5 108
(Dudbridge and Gusnanto, 2008). The overall P-value for
b-defensin falls far short of this threshold. It is not clear,
however, whether this threshold is too conservative for CNV
testing.
There is no evidence from linkage or genome-wide
association studies to support this association. However,
such supporting evidence might not be expected, because
there are no known SNPs that act as even approximate tags
for b-defensin copy number, and because copy number is a
diploid aggregate (the sum of the two copy-number
haplotypes), pedigree-based analysis has little power to
implicate the locus (Hollox et al., 2008). It is therefore not
clear what would constitute an appropriate significance
threshold for this study, which involves typing a single,
candidate CNV. If a number (of the order of a few thousand)
reflecting the full genomic complement of known, distinct
CNVs were used to correct for multiple testing, even that
relatively modest correction would render these data non-
significant overall.
Taken together, our results are consistent with a genuine
but weak association between b-defensin copy number and
psoriasis, with the replication cohorts in this study giving a
better estimate of the true effect size than the discovery study.
Nevertheless, the P-values here fall short of what is required to
regard the evidence as definitively convincing. As association
studies become increasingly powerful, they will increasingly
deal with loci genuinely involved in the causation of
phenotype, but which for large but finite sample sizes will
not reliably reach genome-wide significance. In the instance
of human stature, for example, many heritable factors
genuinely influence the phenotype, but many of these appear
to have individual effect sizes too small to convincingly and
reliably demonstrate in practice (Yang et al., 2010).
MATERIALS AND METHODS
DNA samples
Patients for this study were recruited from three countries. One
collection comes from Nijmegen in the Netherlands, a second from
Erlangen and Mu¨nster in Germany, and the third from Michigan in
the United States. For shorthand, the German collection is referred to
as simply the Erlangen sample, as this was the main organizing
center, even though it includes people who were recruited at eight
different centers. All individuals are of European descent; all sample
collection followed appropriate Local Ethical Review and the
Declaration of Helsinki Principles, including informed written
consent from all subjects.
Most of the Nijmegen sample (407 of 435 individuals) and about
one-quarter of the Erlangen sample (590 of 2,608 individuals) were
included in a previous study of association between psoriasis and the
b-defensin CNV (Hollox et al., 2008). These previously analyzed
individuals have been retyped for both samples, with a newer assay
in the case of the Nijmegen set. In addition, the Erlangen samples
were repurified before retyping. As these samples led to the first
report of association between b-defensin and psoriasis, they are
considered the discovery sample, and this analysis constitutes a re-
evaluation of the originally reported results, using retyped and
repurified samples and a more sophisticated method of data fitting
and analysis. This re-evaluation is somewhat complicated by the fact
that some individuals in the original Hollox study were not included
in the retyped data set.
The newly acquired Nijmegen and Erlangen samples (28 and
2,018 individuals, respectively), along with the Michigan sample
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(5,142 individuals), can be considered an independent replication
sample. Further clinical details can be found in the Supplementary
Material online, Section F. Because of the necessity to first analyze
within each collection center cohort (see below), the new Nijmegen
individuals are not used as part of the replication set in this analysis
as they are too few in number to allow proper fitting of a Gaussian
mixture model to the raw CNV data. For maximum power, this
analysis also considers all discovery and replication samples
combined (including the 28 new Nijmegen samples).
German psoriasis patients were recruited at eight different centers
in Germany (four university hospitals, three psoriasis rehabilitation
hospitals, and one private practice) since 2002. DNAs derived from
blood of cases and controls had been extracted by standard salting
out procedure in 2002–2005 and were all purified in 2009/2010.
DNA purification was performed with the QIAamp DNA Blood Mini
kit (Qiagen, Hilden, Germany) according to the protocol, except for
an elongated elution step of 5minutes. Between October 2005 and
July 2009, DNAs were automatically extracted with the Automatic
Nucleic Acid Isolation System AutoGenFlex 3000 (Parallab, St.
Albans, UK) using the FlexiGene DNA kit (Qiagen). Since July 2009,
DNAs were automatically extracted with Chemagic Magnetic
Separation Module I using the Chemagic DNA Blood Kit (Chema-
gen, Baesweiler, Germany). All DNAs were stored at 4 1C.
Michigan samples consisted of North American Caucasians
collected across the United States with a higher density in the upper
Midwest. Blood-derived DNA from psoriasis patients of any age and
controls of at least 18 years of age was prepared by standard lysis
method followed by phenol extraction and ethanol precipitation
(Nair et al., 1995).
CNV assays and data processing
Four different typing assays were used to determine b-defensin copy
number—three PRT assays (HSPD5, HSPD21, and PRT107A) and a
newer triplex assay that combines the HSPD21 and PRT107A assays
with an indel ratio test. None of these assays were used for all three
sample sets. The Erlangen sample used the HSPD5 assay, which is the
oldest method of the four (Armour et al., 2007). This assay co-
amplifies a heat-shock protein pseudogene upstream of DEFB4 on
chromosome 8 and a single-copy paralog on chromosome 5, yielding
amplicons of 443bp and 447bp, respectively, which then need to be
cleaved with HaeIII to allow their differentiation by electrophoresis.
The Michigan sample used the newer HSPD21 assay (Aldhous et al.,
2010), which co-amplifies the same heat-shock protein as the HSPD5
assay, together with a strictly diploid paralog on chromosome 21. As
the products of HSPD21 are 172bp and 180bp in size, restriction
endonuclease digestion is no longer needed. The Nijmegen sample
received the most comprehensive CNV typing, with two different PRT
assays (HSPD21 and PRT107A) used both individually and together
with a third indel ratio test to achieve a triplex assay (all described in
(Aldhous et al., 2010)). Further details can be found in Supplementary
Materials online, section A.
Data quality, censoring, and heterogeneity
In the Hollox et al. (2008) study, a quality filter was imposed that
censored out any individual whose ratios for the HEX- and FAM-
labeled HSPD5 assay products differed by more than 15% of their
mean. As this filter can lead to bias (individuals with higher defensin
copy number are more likely to be excluded, which can lead to
differential missingness between cases and controls), the current data
were analyzed both with and without censoring; further details are
given in Supplementary Materials online, section B.
CNV cluster fitting and association tests were carried out
separately within each combination of analysis stage (discovery,
replication, and combined) and geographic cohort (Nijmegen,
Erlangen, and Michigan). Further details can be found in Supple-
mentary Materials online, sections D and E.
CNV data
Raw CNV estimates were analyzed for quality parameters (see
Supplementary Materials online, section C) and version 1.44.0 of
CNVtools (Barnes et al., 2008) was used to model distributions as
mixtures of Gaussian component distributions, presumed to corre-
spond to the different integer copy number classes. These analyses
demonstrated differential bias in both the discovery and replication
samples from Erlangen, as evidenced by cases having larger means
and variances than controls for the multiple peaks of the distribution
of CNV estimates (Supplementary Figure S2b online). Because cases
and controls were deliberately interspersed on each typing plate, this
bias cannot be attributed to plate effects, but must be due to some
property of the DNA preparations themselves. The particular
sensitivity of CNV typing to such preparation-specific effects has
been demonstrated in the WTCCC CNV study (Wellcome Trust Case
Control Consortium, 2010) and in studies of CCL3L1 (Field et al.,
2009; Carpenter et al., 2011).
Association testing
Formal testing of association was achieved by using CNVtools to
simultaneously apply mixture model fitting and association testing to
the raw copy number data (see Supplementary Materials online,
Section D). Association was tested under two disease models—a
linear model where the effect on the log-odds of disease is
proportional to the number of copies, and an allelic model where
the odds of disease are allowed to vary freely among copy numbers.
As the optimal combination of parameters for fitting the mixture
model was chosen without simultaneously testing for association
(see previous section), to be conservative, for each cohort analysis
the association testing was run for multiple parameter combinations.
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